Treatment News : Supercomputer Helps Define HIV Capsid Structure

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 29, 2013

Supercomputer Helps Define HIV Capsid Structure

For the first time, scientists have identified the precise atomic structure of the HIV capsid, which is the container of viral genes the virus inserts into human immune cells. This discovery, which was aided by the massively powerful Blue Waters supercomputer at the University of Illinois, Urbana-Champaign, may help in the development of new HIV therapies that would attack the capsid. Since this would be a novel approach to fighting HIV, such therapies would hold the promise of being effective for those who are resistant to other classes of drugs. The findings made the cover of the May 30 issue of the journal Nature.

After using Blue Waters’ computational power to aid in defining the atomic structure of the capsid, the University of Illinois teams ran a simulation through the computer of how the capsid would behave in organic situations. According to investigator Klaus Schulten, a physics professor at the university, the supercomputer is 20 to 50 times more powerful in its computational abilities than the computer his team relied upon only a year before. Such power was necessary to help understand the relatively large capsid, which is composed of some 3 million protein atoms.

These findings and the capacity of Blue Waters have opened the door for drug developers to better understand how their agents are interacting with the capsid, so they can tailor the drug molecules accordingly. The Illinois research team will next pursue such drug therapies in their simulations.

To read the study abstract, click here.

To read a release on the paper, click here.

To watch a YouTube video discussing the findings, click here.

Search: HIV, supercomputer, Blue Waters, University of Illinois, Urbana-Champaign, capsid, Klaus Schulten.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    Poz_Qt
    Columbus
    Ohio


    hollywoodvers1
    Los Angeles
    California


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.